Viking Therapeutics Inc. VKTX announced on Wednesday that it has initiated a Phase 1 trial evaluating VK3019, an ...
On Tuesday, Viking Therapeutics, Inc. (NASDAQ:VKTX) highlighted the final results from its VOYAGE Phase 2b trial of VK2809 in patients with biopsy-confirmed non-alcoholic steatohepatitis (NASH, also ...
Viking Therapeutics (NasdaqCM:VKTX) has begun a Phase 1 clinical trial for VK3019, a dual amylin and calcitonin receptor ...
Results from VENTURE Phase 2 Study of Subcutaneous VK2735 in Obese Patients and Phase 1 Trial of Oral VK2735 in Healthy Subjects to be Presented SAN DIEGO, Oct. 28, 2024 /PRNewswire/ -- Viking ...
First, a bit of detail about these products and potential products. Lilly's drugs -- Mounjaro and Zepbound -- involve the molecule tirzepatide, which acts on glucagon-like peptide-1 (GLP-1) and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results